0001773751-23-000027.txt : 20230227 0001773751-23-000027.hdr.sgml : 20230227 20230227161956 ACCESSION NUMBER: 0001773751-23-000027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230227 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230227 DATE AS OF CHANGE: 20230227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hims & Hers Health, Inc. CENTRAL INDEX KEY: 0001773751 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38986 FILM NUMBER: 23675190 BUSINESS ADDRESS: STREET 1: 2269 CHESTNUT ST STREET 2: #523 CITY: SAN FRANCISCO STATE: CA ZIP: 94123 BUSINESS PHONE: 415-851-0195 MAIL ADDRESS: STREET 1: 2269 CHESTNUT ST STREET 2: #523 CITY: SAN FRANCISCO STATE: CA ZIP: 94123 FORMER COMPANY: FORMER CONFORMED NAME: Oaktree Acquisition Corp. DATE OF NAME CHANGE: 20190412 8-K 1 hims-20230227.htm 8-K hims-20230227
0001773751false00017737512023-02-272023-02-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2023

HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-3898698-1482650
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
(IRS Employer
Identification No.)
2269 Chestnut Street, #523
94123
San Francisco,
California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code:  (415) 851-0195

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each classTrading symbolName of each exchange on which registered
Class A common stock, $0.0001 par valueHIMSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 





Item 2.02.Results of Operations and Financial Condition.
On February 27, 2023, Hims & Hers Health, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter and year ended December 31, 2022. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02.
The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.
Description
99.1  
104Cover Page Interactive Data file (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: February 27, 2023
By:/s/ Oluyemi Okupe
Oluyemi Okupe
Chief Financial Officer
(Principal Financial Officer)


EX-99.1 2 hims-20221231x8xkearningre.htm EX-99.1 Document


Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results

Full year 2022 revenue of $526.9 million, up 94% year-over-year

Q4 2022 record revenue of $167.2 million, up 97% year-over-year

Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million

Eclipses one million subscribers at year end, up 88% year-over-year

Provides Q1 and full year 2023 guidance, with full year 2023 revenue in the range of $735 million to $755 million and Adjusted EBITDA in the range of $20 million to $30 million

Introduces 2025 targets of at least $1.2 billion in revenue and $100 million in Adjusted EBITDA


SAN FRANCISCO, February 27, 2023 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the fourth quarter and full year ended December 31, 2022.

“2022 was a year of outstanding execution across the company, as we surpassed one million Subscribers on the platform and made significant strides in delivering on our mission to make the world feel great through the power of better health,” said Andrew Dudum, co-founder and CEO. “New technological advancements, acquisition of key talent, ongoing brand strength, and operational excellence fueled strong growth across the business. We entered 2023 with tremendous momentum and are poised to drive top-line growth and profitability as we focus on four strategic pillars: building a trusted brand, deploying leading technology, developing innovative products and services, and ensuring clinical excellence, which will enable us to continue to execute on our mission and extend our reach.”

“We are excited by the large market opportunity in front of us. It is clear that our operating model is fueling strong results and momentum. Notably, the transition to positive Adjusted EBITDA in the fourth quarter provides us with additional flexibility to continue building scale,” said Yemi Okupe, CFO. “With the strong foundation we have laid and our track record of operational excellence, we are well-positioned to deliver on the 2023 outlook and longer term goals we’re introducing today.”




Key Business Metrics
(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)


Three Months Ended
December 31,
Year Ended
December 31,

20222021% Change20222021% Change

Subscribers (end of period)1,040 554 88 %1,040 554 88 %
Monthly Online Revenue per Average Subscriber$55 $50 10 %$53 $51 %
Subscriptions (end of period)1,116 609 83 %1,116 609 83 %
Net Orders1,855 1,063 75 %6,122 3,504 75 %
AOV$87 $74 18 %$82 $74 11 %

Revenue
(In Thousands, Unaudited)


Three Months Ended
December 31,
Year Ended
December 31,

20222021% Change20222021% Change
 

Online Revenue
$161,162$78,312106 %$502,507$259,17094 %
Wholesale Revenue
6,0416,387(5)%24,40912,70892 %
Total revenue
$167,203$84,69997 %$526,916$271,87894 %

Please see the discussion in “Revenue and Key Business Metrics” in Item 7 (Management’s Discussion & Analysis of Financial Condition and Results of Operations) of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for a discussion of recent and upcoming changes to our key business metrics.

Fourth Quarter 2022 Financial Highlights
Revenue was $167.2 million for the fourth quarter of 2022 compared to $84.7 million for the fourth quarter of 2021, an increase of 97% year-over-year.
Gross margin was 79% for the fourth quarter of 2022 compared to 73% for the fourth quarter of 2021.
Net loss was $(10.9) million in the fourth quarter of 2022 compared to $(31.2) million for the fourth quarter of 2021.
Adjusted EBITDA was $3.9 million for the fourth quarter of 2022 compared to $(7.1) million for the fourth quarter of 2021.

Full Year 2022 Financial Highlights
Revenue was $526.9 million for the year ended December 31, 2022 compared to $271.9 million for the year ended December 31, 2021, an increase of 94% year-over-year.
Gross margin was 78% for the year ended December 31, 2022 compared to 75% for the year ended December 31, 2021.



Net loss was $(65.7) million for the year ended December 31, 2022 compared to $(107.7) million for the year ended December 31, 2021.
Adjusted EBITDA was $(15.8) million for the year ended December 31, 2022 compared to $(30.1) million for the year ended December 31, 2021.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States (“U.S. GAAP”), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading “Non-GAAP Financial Measures”.

2023 Financial Outlook

Hims & Hers is providing the following 2023 guidance:

For the first quarter 2023, we expect:
Revenue of $175 million to $180 million.
Adjusted EBITDA of $3 million to $6 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

For the full year 2023, we expect:
Revenue of $735 million to $755 million.
Adjusted EBITDA of $20 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.

2025 Financial Targets

Hims & Hers has demonstrated a consistent track record of execution driven by the strength of its business model and operational excellence, which is fueling strong top line growth and Adjusted EBITDA profitability. Given its large market opportunity and growing customer demand, the Company is providing financial targets for the full year 2025, which include:
Revenue of at least $1.2 billion.
Adjusted EBITDA of at least $100 million.

The guidance and targets provided above constitute forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.




Conference Call

Hims & Hers will host a conference call to review the fourth quarter and full year 2022 results on February 27, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.forhims.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believe,” “estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,” “plan,” “may,” “will,” “potential,” “project,” “predict,” “continue,” “could,” or “should,” or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, our market opportunity, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies, the success of our business model, our ability to scale our business, the growth of certain of our categories and the impact of our acquisitions, our ability to expand the scope of our offerings and experiences, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer product quality laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us



may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.




Key Business Metrics

As our business grows and evolves, we continually and strategically review our key metrics. Beginning with our 2022 Annual Report on Form 10-K, we commenced reporting “Subscribers” and “Monthly Online Revenue Per Average Subscriber” as additional key business metrics (as defined below). As a result of broadening the number of health and wellness categories the Company serves, we believe it is important to measure the holistic relationship that we have with our customers. Additionally, the recurring nature of our revenue necessitates the need for metrics that provide greater visibility into both the breadth and engagement of users on our platform. We believe Subscribers represent a more accurate reflection of the number of distinct users that we have on our platform relative to the number of subscriptions, and beginning with the three months ending March 31, 2023, we anticipate no longer reporting “Subscriptions” as a key business metric. Monthly Online Revenue per Average Subscriber reflects how users’ engagement with products across our platform is evolving. These changes are intended to better align our key business metrics with our internal priorities and business plans.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

“Subscribers” are customers who have one or more Subscriptions pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

“Subscriptions” are defined as the number of customer agreements where the customer has agreed to be automatically billed on a recurring basis at a defined cadence. The billing cadence is typically defined as a number of months (for example, billed every month or every three months). Subscriptions are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscription billing is preferred by many of our customers because most of the products and services we make available are most effective when taken consistently and continuously. Customers can cancel subscriptions in between billing periods to stop receiving additional products and services and can reactivate subscriptions to continue receiving additional products and services. Subscriptions are sometimes also referred to by us as “subscription memberships” or “memberships.”

“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our



platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders (each as defined above).



CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share and Per Share Data, Unaudited)
December 31,
 20222021
Assets
Current assets:
Cash and cash equivalents$46,772 $71,784 
Short-term investments132,853 175,490 
Inventory21,562 13,558 
Prepaid expenses and other current assets15,408 9,073 
Total current assets216,595 269,905 
Restricted cash856 856 
Goodwill110,881 110,881 
Intangibles, net21,841 25,890 
Operating lease right-of-use assets4,936 5,111 
Other long-term assets11,232 7,942 
Total assets$366,341 $420,585 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable$32,363 $19,640 
Accrued liabilities12,448 12,194 
Deferred revenue1,472 3,188 
Earn-out payable— 42,834 
Operating lease liabilities1,658 1,365 
Total current liabilities47,941 79,221 
Operating lease liabilities3,649 4,117 
Earn-out liabilities2,975 1,999 
Other long-term liabilities35 629 
Total liabilities54,600 85,966 
Commitments and contingencies
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,051,689 and 196,414,363 shares issued and outstanding as of December 31, 2022 and 2021, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2022 and 2021
21 20 
Additional paid-in capital656,626 613,687 
Accumulated other comprehensive loss(277)(137)
Accumulated deficit(344,629)(278,951)
Total stockholders' equity311,741 334,619 
Total liabilities and stockholders' equity$366,341 $420,585 



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In Thousands, Except Share and Per Share Data, Unaudited)
 Three Months Ended
December 31,
Year Ended
December 31,
 2022202120222021
Revenue$167,203 $84,699 $526,916 $271,878 
Cost of revenue34,866 22,601 118,194 67,384 
Gross profit132,337 62,098 408,722 204,494 
Gross margin %79 %73 %78 %75 %
Operating expenses:(1)
Marketing85,542 42,707 272,587 135,902 
Operations and support22,521 13,845 77,403 47,593 
Technology and development8,311 5,572 29,237 22,379 
General and administrative27,568 21,539 98,192 113,662 
Total operating expenses143,942 83,663 477,419 319,536 
Loss from operations(11,605)(21,565)(68,697)(115,042)
Other income (expense):
Change in fair value of liabilities(942)(9,808)70 3,802 
Other income, net1,519 125 2,918 445 
Total other income (expense), net577 (9,683)2,988 4,247 
Loss before income taxes(11,028)(31,248)(65,709)(110,795)
Benefit from income taxes121 87 31 3,136 
Net loss(10,907)(31,161)(65,678)(107,659)
Other comprehensive income (loss)185 (85)(140)(126)
Total comprehensive loss$(10,722)$(31,246)$(65,818)$(107,785)
Net loss per share attributable to common stockholders:
Basic and diluted$(0.05)$(0.15)$(0.32)$(0.58)
Weighted average shares outstanding:
Basic and diluted206,140,283 201,363,338 204,516,120 186,781,537 
______________ 
(1)Includes stock-based compensation expense as follows (in thousands):


Three Months Ended
December 31,
Year Ended
December 31,
2022202120222021
Marketing$1,512 $4,718 $4,648 $9,664 
Operations and support836 302 2,684 2,735 
Technology and development1,328 989 4,327 4,481 
General and administrative8,674 5,943 31,158 50,331 
Total stock-based compensation expense$12,350 $11,952 $42,817 $67,211 





CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands, Unaudited)
Year Ended December 31,
20222021
Operating activities
Net loss$(65,678)$(107,659)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization7,474 4,075 
Stock-based compensation42,817 67,211 
Change in fair value of liabilities(70)(3,802)
Warrant expense in connection with Merger— 154 
Amortization of debt issuance costs— 144 
Net amortization on securities146 2,166 
Benefit for deferred taxes(594)(3,388)
Impairment of long-lived assets1,127 — 
Non-cash operating lease cost1,605 1,510 
Non-cash acquisition-related costs837 1,182 
Non-cash other— 540 
Changes in operating assets and liabilities:
Inventory(8,004)(9,628)
Prepaid expenses and other current assets(6,335)3,200 
Other long-term assets17 (58)
Accounts payable12,723 9,853 
Accrued liabilities909 197 
Deferred revenue(1,716)1,412 
Operating lease liabilities(1,605)(1,521)
Earn-out payable(10,184)— 
Net cash used in operating activities(26,531)(34,412)
Investing activities
Purchases of investments(187,700)(266,633)
Maturities of investments194,259 158,375 
Proceeds from sales of investments35,846 3,465 
Investment in website and mobile application development and internal-use software(4,533)(4,175)
Purchases of property, equipment, and intangible assets(2,714)(832)
Deferred consideration paid for acquisitions(459)— 
Acquisition of businesses, net of cash acquired— (46,468)
Net cash provided by (used in) investing activities34,699 (156,268)
Financing activities
Pre-closing stock repurchase— (22,027)
Proceeds from issuance of common stock upon Merger— 197,686 
Proceeds from PIPE— 75,000 
Payments for transaction costs related to securities issuances— (12,851)
Proceeds from repayment of promissory notes associated with vested and unvested shares— 1,193 
Proceeds from exercise of Class A common stock warrants, net of redemption payments— 787 
Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations2,246 1,253 
Payments for taxes related to net share settlement of equity awards(3,901)(5,998)
Payments for earn-out consideration for acquisitions(32,650)— 
Proceeds from employee stock purchase plan1,178 — 
Net cash (used in) provided by financing activities(33,127)235,043 
Foreign currency effect on cash and cash equivalents(53)(73)
(Decrease) increase in cash, cash equivalents, and restricted cash(25,012)44,290 
Cash, cash equivalents, and restricted cash at beginning of period72,640 28,350 
Cash, cash equivalents, and restricted cash at end of period$47,628 $72,640 
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents$46,772 $71,784 
Restricted cash856 856 
Total cash, cash equivalents, and restricted cash$47,628 $72,640 
Supplemental disclosures of cash flow information
Cash paid for taxes$636 $338 
Non-cash investing and financing activities
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase— 125 
Conversion of redeemable convertible preferred stock to common stock— 249,837 
Assumption of Merger warrants liability— 51,814 
Redemption/exercise of Class A common stock warrants— 37,834 
Conversion of Series D preferred stock warrants to Class A common warrants— 1,160 
Right-of-use asset obtained in exchange for lease liability1,206 — 
Vesting of early-exercised stock options, net of cancelations197 227 
Common stock issued, contingent consideration, and liabilities assumed in acquisition of businesses— 99,958 



Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes (i) acquisition professional services; and (ii) consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), impairment of long-lived assets, income taxes, change in fair value of liabilities, net interest, one-time bonuses and warrant expense in connection with the combination of Hims, Inc. (“Hims”) and Oaktree Acquisition Corp. (“OAC”), with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the “Merger”), and amortization of debt issuance costs. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any



unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.

Net Loss to Adjusted EBITDA Reconciliation
(In Thousands, Unaudited)
 Three Months Ended
December 31,
Year Ended
December 31,
 2022202120222021
 
Revenue$167,203 $84,699 $526,916 $271,878 
Net loss (10,907)(31,161)(65,678)(107,659)
Stock-based compensation12,350 11,952 42,817 67,211 
Depreciation and amortization2,010 1,630 7,474 4,075 
Acquisition-related costs1,117 891 1,192 8,105 
Impairment of long-lived assets— — 1,127 — 
(Benefit) provision for income taxes (121)(87)(31)(3,136)
Change in fair value of liabilities942 9,808 (70)(3,802)
Interest (income) / expense, net(1,472)(92)(2,610)(390)
Merger bonuses— — — 5,219 
Warrant expense in connection with Merger— — — 154 
Amortization of debt issuance costs— — — 144 
Adjusted EBITDA$3,919 $(7,059)$(15,779)$(30,079)
Net loss as a % of revenue(7)%(37)%(12)%(40)%
Adjusted EBITDA margin%(8)%(3)%(11)%


Contacts:
Investor Relations
Alice Lopatto
Investors@forhims.com

Media Relations
Press@forhims.com

EX-101.SCH 3 hims-20230227.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hims-20230227_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 hims-20230227_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 27, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 27, 2023
Entity Registrant Name HIMS & HERS HEALTH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38986
Entity Tax Identification Number 98-1482650
Entity Address, Address Line One 2269 Chestnut Street, #523
Entity Address, Postal Zip Code 94123
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
City Area Code 415
Local Phone Number 851-0195
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.0001 par value
Trading Symbol HIMS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001773751
Amendment Flag false
XML 7 hims-20230227_htm.xml IDEA: XBRL DOCUMENT 0001773751 2023-02-27 2023-02-27 0001773751 false 8-K 2023-02-27 HIMS & HERS HEALTH, INC. DE 001-38986 98-1482650 2269 Chestnut Street, #523 94123 San Francisco CA 415 851-0195 false false false false Class A common stock, $0.0001 par value HIMS NYSE false 2023-02-27 2023-02-27 EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://forhims.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hims-20230227.htm hims-20221231x8xkearningre.htm hims-20230227.xsd hims-20230227_lab.xml hims-20230227_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hims-20230227.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "hims-20230227.htm" ] }, "labelLink": { "local": [ "hims-20230227_lab.xml" ] }, "presentationLink": { "local": [ "hims-20230227_pre.xml" ] }, "schema": { "local": [ "hims-20230227.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hims", "nsuri": "http://forhims.com/20230227", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hims-20230227.htm", "contextRef": "ia7fd77bedc664288867c569a8d2d2cb2_D20230227-20230227", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://forhims.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hims-20230227.htm", "contextRef": "ia7fd77bedc664288867c569a8d2d2cb2_D20230227-20230227", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001773751-23-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001773751-23-000027-xbrl.zip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end